A groundbreaking study has uncovered a fascinating aspect of our immune system: a tissue protein that acts as a vital 'traffic controller' for immune cells can be commandeered by a common virus, thereby compromising our immune defenses.
This significant research, conducted by teams from Monash University and the Lions Eye Institute, was published today in the esteemed journal Nature. It sheds light on a crucial mechanism that governs how immune cells organize their responses to threats and illustrates how a prevalent virus can manipulate this process for its own advantage.
At the heart of this discovery is a molecule known as CD44, which plays a pivotal role in orchestrating the network of support cells that are essential for effective immune system operation. These support cells, particularly stromal cells, facilitate the movement of immune cells, enabling them to communicate and share critical information necessary for combating infections, responding to vaccinations, and sustaining overall health.
In a remarkable revelation, the researchers found that cytomegalovirus (CMV) is capable of hijacking this immune control system by producing a protein that interferes with the function of CD44 on stromal cells. This interference disrupts the flow of immune cell traffic right at its origin, significantly weakening the body's ability to mount an antiviral response.
According to the lead researcher, Professor Mariapia Degli-Esposti, who heads the Experimental and Viral Immunology department at Monash Biomedicine Discovery Institute and also leads Experimental Immunology at the Lions Eye Institute, these findings drastically alter our understanding of the signals that govern immune function. She eloquently compares the immune system to a bustling city, where countless cells are vigilantly working to protect us. "CD44 serves as the main traffic controller; it ensures that immune cells are on the move and coordinates their interactions at precisely the right places and times. Our study highlights CD44 as a key regulator of immune cell movement and communication, revealing that viruses can undermine immunity not just by directly attacking immune cells, but also by targeting the vital tissue infrastructure that these cells depend on."
This perspective introduces a novel way to view how viruses interfere with immune responses. Dr. Chris Andoniou, co-lead researcher and a Senior Research Fellow at both Monash Biomedicine Discovery Institute and the Lions Eye Institute, emphasized the broad implications of these findings for human health. He stated, "Given CD44's crucial role in managing immune activity, the viral protein identified in our research could inspire the development of new medications aimed at precisely reducing harmful inflammation. By studying the strategies employed by the virus, we might design therapeutic agents that safely mitigate excessive immune responses, which could be beneficial in the treatment of autoimmune diseases. Although we are still in the early phases of this research, the potential for exciting developments is profound."
This important research received backing from the Australian Research Council and the National Health and Medical Research Council, underscoring its significance in the scientific community.
